Clinical trials: Affective Disorder
Major Depressive Disorder
Ketamine in Adolescents With Treatment-Resistant Depression
This study will test the use of ketamine for treatment of depression in adolescents that have not responded to other treatments. We will also examine neurobiological mechanisms of treatment.
- Trial name
- NCT02078817
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Minnesota
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). This study will investigate the safety, efficacy, and tolerability of DVS SR versus escitalopram in women with major…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00406640
- Testing
- Desvenlafaxine succinate sustained-release (DVS SR), Escitalopram
- Where
- 70 sites in United States, Argentina and 4 more
- Volunteers
- 595 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder, Depression
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who…
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- Polaris (NCT01360632)
- Testing
- OPC-34712 + ADT
- Where
- 71 sites in United States, Canada and 5 more
- Volunteers
- 1,539 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder
The purpose of this study is to assess the efficacy, safety and tolerability of 8-week treatment with Vortioxetine (Lu AA21004), once daily (QD), in Japanese participants with major depressive disorder.
- Trial name
- NCT01355081
- Testing
- Vortioxetine
- Where
- 32 sites in Japan
- Volunteers
- 366 people
- Sponsor
- Takeda
Major Depressive Disorder
Lipopolysaccharide (LPS) Challenge in Depression
LPS Challenge in Individuals with Major Depressive Disorder
- Trial name
- NCT03142919
- Testing
- Lipopolysaccharide
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Laureate Institute for Brain Research, Inc.
Bipolar Depression
Medication, Weight Gain and GI Hormones
This is an 8 week study that compares two medications. One medication is olanzapine (5-20 mg daily) whereas the other medication is an orally disintegrating medication.
- Trial name
- NCT00384332
- Testing
- orally-disintegrating olanzapine, regular olanzapine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Schizophrenia, Schizophreniform Disorder
Omega-3 Dietary Supplements in Schizophrenia
This 16-week placebo-control study looks to investigate whether patients with schizophrenia for two years or less may benefit from omega-3 supplements.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT01786239
- Testing
- Risperidone, Omega-3 capsules
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Delbert Robinson
Post Partum Depression
Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression
Postpartum depression is a non-psychotic major or minor depressive episode that occurs during pregnancy or within 12 months of post-partum period.
- Trial name
- NCT04011592
- Testing
- Ketamine 0.5 mg/kg, Ketamine 0.2 mg/kg
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- The University of Texas Health Science Center, Houston
Schizophrenia, Schizoaffective Disorder
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
The purpose of this study is to determine whether the administration of omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA), can be useful both to reduce coronary artery disease (CAD) risk and illness…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder
- Trial name
- CAD (NCT00167310)
- Testing
- Eicosapentaenoic acid (omega-3 fatty acid)
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder
Closed-loop Optimized rTMS for Depression
Targeted and individualized treatments for mental health disorders are critically needed. Repetitive transcranial magnetic stimulation (rTMS) represents the front-line of new and innovative approaches to normalizing dysfunctional…
- Trial name
- NCT04142320
- Testing
- Neuronavigated rTMS
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Stanford University
Major Depression
PRIME Care (PRecision Medicine In MEntal Health Care)
The focus of this application is on the impact of providing depressed Veterans and their providers with the results of pharmacogenetic (PGx) testing for psychotropic medications.
- Trial name
- PRIME Care (NCT03170362)
- Testing
- Pharmacogenetic Test
- Where
- 24 sites in United States
- Volunteers
- 1,944 people
- Sponsor
- VA Office of Research and Development
Bipolar Disorder
Gao NARASD Lithium Study
This study is a 4-month open-label study of lithium in the acute treatment of patients with bipolar I or II disorder. Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as…
- Trial name
- NCT02909504
- Testing
- Lithium
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Keming Gao
Seasonal Affective Disorder
Research Study of Treatment for Winter Depression With Different Colors of Light
The specific aim of this study is to test the hypothesis that light stimuli concentrated around 467 nm will evoke a significantly stronger therapeutic response in SAD patients compared to light stimuli concentrated around 657 nm…
- Trial name
- NCT00269633
- Testing
- Blue Light Box 467 nm, Red Light Box 657 nm
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Thomas Jefferson University
Bipolar Disorder, Mania
An Extended-Release Form of Clonidine as an Anti-Manic Agent: An Add-on, Open-Label Study
The investigators plan to to study an extended-release form of clonidine, which the investigators hope will be even better tolerated than the immediate-release form, as an antimanic agent.
- Trial name
- NCT03065933
- Testing
- extended-release clonidine
- Volunteers
- 5 people
- Sponsor
- Mclean Hospital
Major Depressive Disorder
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
This is a Phase 2 clinical study evaluating the safety and effectiveness of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
- Trial name
- NCT04479852
- Testing
- SP-624
- Where
- 39 sites in United States
- Volunteers
- 319 people
- Sponsor
- Sirtsei Pharmaceuticals, Inc.
Schizophrenia, Schizo Affective Disorder
Brain Stimulation and Cognitive Training - Efficacy
People with serious mental illness often experience difficulties with thinking skills like memory. These difficulties can make it harder to perform day-to-day activities.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Bipolar Disorder
- Trial name
- NCT05111548
- Testing
- tDCS (Active), BrainHQ, tDCS (Inactive)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Michigan
Bipolar Depression
A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression
The main goal of this study is to help answer the following research question(s) and not to treat the child's illness. Can this study drug make children with bipolar depression feel better? Does this study drug work better than a…
- Trial name
- NCT00844857
- Testing
- Olanzapine Fluoxetine Combination (OFC)
- Where
- 7 sites in United States, Russia
- Volunteers
- 291 people
- Sponsor
- Eli Lilly and Company
Anxiety Disorder, Depressive Disorder
Feasibility of a Culturally Adapted Emotional-Behavioral Prevention Program for American Indian Children
American Indians (AI) are at greater risk for anxiety and depression early in life. This is concerning given the potential negative effects of these conditions across the lifespan (substance use, suicide).
- Trial name
- NCT05371665
- Testing
- Culturally Adapted Cognitive-Behavioral Prevention and Early Intervention (PEI) Program
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Montana State University
Major Depressive Disorder
Vagal Nerve Stimulation for Treatment Resistant Major Depression
The purpose of this study is to 1) explore whether vagal nerve stimulation (nVNS) using a hand- held non-invasive device (gammaCore™) works to treat depression and 2) to confirm gammaCore™'s safety profile.
- Trial name
- NCT04990687
- Testing
- gammaCore™
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Alabama at Birmingham
Major Depressive Disorder (MDD)
Preventing Relapse After Successful Electroconvulsive Therapy for Depression
The present project is designed to study two promising relapse prevention strategies in an RCT. This will be the first project worldwide to study the effects of a personalized ECT treatment algorithm in the continuation phase of…
- Trial name
- PRASED (NCT06751875)
- Testing
- Lithium
- Where
- Belgium
- Volunteers
- 96 people
- Sponsor
- Universiteit Antwerpen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.